Literature DB >> 18381533

Neonatal antibiotic treatment is a risk factor for early wheezing.

Bernt Alm1, Laslo Erdes, Per Möllborg, Rolf Pettersson, S Gunnar Norvenius, Nils Aberg, Göran Wennergren.   

Abstract

OBJECTIVE: The use of antibiotics in infancy and subsequent changes in the intestinal bacterial flora have been discussed as risk factors for the development of asthma. However, it has been difficult to exclude the possibility that antibiotics have been given in early episodes of wheezing. As a result, there has been a risk of reverse causation. To minimize the risk of reverse causation, we have focused on the effect of antibiotics that are already administered on the neonatal ward.
METHODS: In a cohort study of infants born in western Sweden in 2003, we studied the development of wheezing. The families of the infants were randomly selected and sent a questionnaire at child ages 6 and 12 months. The response rate was 68.5% to the 6-month questionnaire and 68.9% to the 12-month questionnaire.
RESULTS: At 12 months, 20.2% of infants had had 1 or more episodes of wheezing, and 5.3% had had 3 or more episodes. Inhaled corticosteroids had been taken by 4.1% of the infants. Independent risk factors for wheezing disorder treated with inhaled corticosteroids were neonatal antibiotic treatment, male gender, gestational age of <37 weeks, having a mother with asthma, having a sibling with asthma or eczema, and breastfeeding for <5 months.
CONCLUSIONS: Treatment with antibiotics in the neonatal period was an independent risk factor for wheezing that was treated with inhaled corticosteroids at 12 months of age. These results indirectly support the hypothesis that an alteration in the intestinal flora can increase the risk of subsequent wheezing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381533     DOI: 10.1542/peds.2007-1232

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  49 in total

Review 1.  The human microbiome and its potential importance to pediatrics.

Authors:  Coreen L Johnson; James Versalovic
Journal:  Pediatrics       Date:  2012-04-02       Impact factor: 7.124

Review 2.  Role of the gut microbiota in defining human health.

Authors:  Kei E Fujimura; Nicole A Slusher; Michael D Cabana; Susan V Lynch
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

Review 3.  Asthma: epidemiology, etiology and risk factors.

Authors:  Padmaja Subbarao; Piush J Mandhane; Malcolm R Sears
Journal:  CMAJ       Date:  2009-09-14       Impact factor: 8.262

4.  Neonatal Antibiotic Use: How Much Is Too Much?

Authors:  Dustin D Flannery; Karen M Puopolo
Journal:  Pediatrics       Date:  2018-09       Impact factor: 7.124

5.  Neonatal early-onset sepsis evaluations among well-appearing infants: projected impact of changes in CDC GBS guidelines.

Authors:  S Mukhopadhyay; E C Eichenwald; K M Puopolo
Journal:  J Perinatol       Date:  2012-07-19       Impact factor: 2.521

6.  Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis.

Authors:  Paul C Blainey; Carlos E Milla; David N Cornfield; Stephen R Quake
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

Review 7.  A 'culture' shift: Application of molecular techniques for diagnosing polymicrobial infections.

Authors:  Yi Zhang; Anne Hu; Nadya Andini; Samuel Yang
Journal:  Biotechnol Adv       Date:  2019-02-20       Impact factor: 14.227

8.  Risk for asthma in offspring of asthmatic mothers versus fathers: a meta-analysis.

Authors:  Robert H Lim; Lester Kobzik; Morten Dahl
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

9.  American Pediatric Society presidential address 2008: research in early life - benefit and promise.

Authors:  William W Hay
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

10.  Why do former preterm infants wheeze?

Authors:  Richard J Martin; Y S Prakash; Anna Maria Hibbs
Journal:  J Pediatr       Date:  2012-12-20       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.